Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025

Takao Inoue, Head of the Division of Molecular Targeted and Gene Therapy Products, National Institute of Health Sciences R&D is picking up speed in the field of small interfering RNA (siRNA) therapies. What has been the stronghold of Alnylam Pharmaceuticals...read more